PLX at a glance
Protalix BioTherapeutics, Inc. (PLX, SEC CIK 1006281) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Protalix BioTherapeutics, Inc. (PLX) reported revenue of $52.7 million (down 1.2% from FY2024) and a net loss of $6.6 million. Diluted EPS was -$0.08.
- As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Protalix BioTherapeutics, Inc. (PLX) shares worth $28.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $52.7M
- −1.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 21 funds
- $28.8M · −3 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to previously disclosed risk factors in the 2025 Form 10-K
- No material changes to risk factors reported in the June 30, 2026 Form 10-Q
Management Discussion & Analysis
- Q3 revenue $21.925M, up from $17.851M YoY, driven by selling-goods revenue of $21.834M
- Q3 operating margin 18.5% vs 11.9% YoY, with operating income $4.047M vs $2.131M
- Best segment Chiesi, Q3 sales $13.138M vs $8.763M; worst Fiocruz, $4.365M vs $6.105M
- Cash and short-term deposits $48.5M; nine-month operating cash flow $15.529M vs $(14.023)M YoY
- Management expects rising R&D spending for the RELEASE study, with funds sufficient for at least 12 months
AI summary of the PLX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $21.9M and net income $4.0M, up from $17.9M and $2.4M year over year
- Nine-month revenue $75.6M, including $25.0M Chiesi milestone, versus $43.6M in 2025
Item 2.02: Results of Operations and Financial Condition
- Press release covers Protalix’s quarter ended September 30, 2026
- Business and clinical updates accompany the quarterly financial results
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results covered quarter ended June 30, 2026
- Business and clinical update accompanied financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $19.9M, up from $15.7M, with product sales rising to $19.8M on stronger Elfabrio demand
- Six-month revenue $53.6M included a $25.0M Chiesi milestone, making recurring commercial revenue quality especially important
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected all eight director nominees, maintaining board continuity; Amos Bar Shalev received the highest withheld vote count at 6,461,724
- Executive compensation approved on advisory basis, with 28,368,614 votes for and 6,683,937 against
AI summaries of PLX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PLX
Don't miss the next PLX filing
- Alerts as it files. A push when PLX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PLX, by share count.
- Ask anything. An AI agent that reads every PLX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Elze Christian | A | Sep 3, 2026 | 17,000 | - |
| Elze Christian | A | Sep 3, 2026 | 8,500 | - |
| Ben Zvi Shmuel | A | Sep 3, 2026 | 17,000 | - |
| Ben Zvi Shmuel | A | Sep 3, 2026 | 8,500 | - |
| Forster Eliot | A | Sep 3, 2026 | 17,000 | - |
| Forster Eliot | A | Sep 3, 2026 | 8,500 | - |
| Melincoff Gwen A | A | Sep 3, 2026 | 17,000 | - |
| Melincoff Gwen A | A | Sep 3, 2026 | 8,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $53.4M | $52.7M |
| Operating Income | $10.5M | $3.9M | -$5.5M |
| Net Income | $8.3M | $2.9M | -$6.6M |
| Op. Margin | - | 7.3% | -10.4% |
| Net Margin | - | 5.5% | -12.5% |
| Balance Sheet | |||
| Total Assets | $84.4M | $73.4M | $82.3M |
| Equity | - | $43.2M | $48.2M |
| ROE | - | 6.8% | -13.7% |
| Per Share | |||
| EPS | $0.09 | $0.04 | $-0.08 |
| Cash Flow | |||
| Operating CF | - | $8.7M | -$12.0M |
| CapEx | - | $1.3M | $1.6M |
Source: XBRL data in Protalix BioTherapeutics, Inc. (PLX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PLX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 21 | $28.8M |
| Q2 2026 | 24 | $23.2M |
| Q1 2026 | 21 | $18.5M |
| Q4 2025 | 19 | $14.6M |
| Q3 2025 | 18 | $16.4M |
| Q2 2025 | 17 | $11.9M |
| Q1 2025 | 11 | $8.8M |
| Q4 2024 | 5 | $4.6M |
- Goldman Sachs Group+413.4K (+87%)
- Dimensional Fund Advisors+223.6K (+45%)
- State Street Corp+173.5K (+18%)
- BlackRock+154.1K (+4%)
- Bank of America Corp+63.4K (+122%)
- Renaissance Technologies LLC−107.9K (-10%)
- AQR Capital Management−105.3K (-63%)
- JPMorgan Chase & Co−92.9K (-70%)
- Northern Trust−90.6K (-10%)
- Citadel Advisors LLC−53.0K (-16%)
- Millennium Management−171.5K
- Equitable Holdings Inc−13.2K
- FMR LLC (Fidelity)−3.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 136 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PLX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| SC 13G | Jul 29, 2026 | - | - | |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 8-K | May 21, 2026 | - | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Mar 18, 2026 | - | Analysis | - |
| 10-K | Mar 18, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| SC 13G | Mar 4, 2026 | - | - | |
| 8-K | Feb 11, 2026 | - | - | |
| 8-K | Jan 30, 2026 | - | - | |
| 8-K | Jan 5, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
PLX SEC filings: frequently asked questions
Which institutions hold PLX stock?
As of September 30, 2026, the largest Protalix BioTherapeutics, Inc. (PLX) holders among the 13F filers tracked by SignalX were BlackRock ($11.6 million), State Street Corp ($3.2 million), Renaissance Technologies LLC ($2.7 million), Goldman Sachs Group ($2.5 million), Northern Trust ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PLX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Protalix BioTherapeutics, Inc. (PLX) reported revenue of $52.7 million (down 1.2% from FY2024) and a net loss of $6.6 million. Diluted EPS was -$0.08. The figures come from the XBRL data in the 10-K.
What did PLX report in its latest 8-K?
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $21.9M and net income $4.0M, up from $17.9M and $2.4M year over year.
What are the latest PLX SEC filings?
Protalix BioTherapeutics, Inc. (PLX) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on September 9, 2026.
What is PLX's SEC CIK number?
Protalix BioTherapeutics, Inc. (PLX)'s SEC Central Index Key (CIK) is 1006281. EDGAR lists every PLX filing under that number.
Ask anything about PLX
The research agent reads PLX's filings, financials, insider trades and 13F holders, then answers with sources.